

[Home](#) | [Über das Meeting](#) | [Kontakt](#)  
| [Impressum](#) | [Englisch](#)

27. Deutscher  
Krebekongress



Berlin 2006

**27. Deutscher  
Krebekongress  
Deutsche  
Krebekgesellschaft e.V.**

**22. bis 26.03.2006, Berlin**

erschienen bei

gms

Konferenz

Krebekongress 2006

Suche in Krebekongress  
2006


Email diesen Artikel

Ausgabe Formate

XML

Meeting Abstract

**Darbepoetin alfa as  
primary prophylaxis of  
anaemia in breast cancer  
patients treated  
preoperatively with  
Docetaxel, Doxorubicin,  
Cyclophosphamide**

✉  **Friederike Marquardt** -  
*Universitätsklinikum, Frankfurt am  
Main, Deutschland*

✉ **Sibylle Loibl** -  
*Universitätsklinikum, Frankfurt am  
Main*

✉ **Gunter von Minckwitz** -  
*Universitätsklinikum, Frankfurt am  
Main*

✉ **Manfred Kaufmann** -  
*Universitätsklinikum, Frankfurt am  
Main*

27. Deutscher Krebekongress.  
Berlin, 22.-26.03.2006.  
Düsseldorf, Köln: German Medical  
Science; 2006. Doc PO033

The electronic version of this  
article is the complete one and  
can be found online at:

**Published: 20-03-2006**

Suche in Medline nach

Marquardt F

Loibl S

von Minckwitz G

Kaufmann M

Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Gliederung

Top

Text

---

## Text

Docetaxel, Adriamycin, Cyclophosphamide (TAC) is considered today as one treatment option for patients with node-positive primary breast cancer. However, treatment is associated with anaemia grade 1-4 (2-4) in up to 95% (36%) of patients. We prospectively investigated the use of a primary prophylaxis with Darbepoetin alfa once every 3 weeks in 35 patients receiving six to eight cycles of TAC as neoadjuvant treatment for breast cancer. Darbepoetin treatment started on day 1 of a TAC cycle if haemoglobin (Hb) was  $\leq 14.0$  g/dl. Dosage was adapted to  $9 \mu\text{g}/\text{kg}$  if Hb was  $\leq 13.0$  g/dl on day 21 of the previous cycle, to  $4.5 \mu\text{g}/\text{kg}$  if Hb was between 13.0 and 14.0 g/dl and was discontinued if Hb increased to  $\geq 14$  g/dl. The primary aim was to prevent Hb levels  $\leq 12$  g/dl before surgery. During 112 (50.2%) and 93 (41.7%) of 223 cycles,  $4.5 \mu\text{g}/\text{kg}$  and  $9 \mu\text{g}/\text{kg}$  Darbepoetin were given, respectively. Dosage was decreased from 9 to  $4.5 \mu\text{g}/\text{kg}$  in 21 (60%) patients and 28 (12.4%) cycles. Treatment was discontinued due to Hb  $> 14.0$  g/dl in 12 (34.3%) patients and 13

(5.4%) cycles. Hb level on day 21 of the last cycle was  $\leq 12.0$  g/dl in 4 (11.4%) patients. Eighteen (51.4%) patients during 36 (16.1%) cycles showed Hb levels  $\leq 12$  g/dl throughout treatment. No NCI-CTC grade 2 to 4 anaemia was observed. Symptoms of fatigue (FACT-AN) decreased slightly throughout treatment. Anaemia during TAC chemotherapy can be avoided by a single injection of Darbepoetin alfa every 3 weeks.